JP2015523355A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523355A5 JP2015523355A5 JP2015517405A JP2015517405A JP2015523355A5 JP 2015523355 A5 JP2015523355 A5 JP 2015523355A5 JP 2015517405 A JP2015517405 A JP 2015517405A JP 2015517405 A JP2015517405 A JP 2015517405A JP 2015523355 A5 JP2015523355 A5 JP 2015523355A5
- Authority
- JP
- Japan
- Prior art keywords
- irinotecan
- administered
- leucovorin
- dose
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004768 irinotecan Drugs 0.000 claims description 74
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 70
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 32
- 229960002949 fluorouracil Drugs 0.000 claims description 32
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 29
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 29
- 235000008191 folinic acid Nutrition 0.000 claims description 29
- 239000011672 folinic acid Substances 0.000 claims description 29
- 229960001691 leucovorin Drugs 0.000 claims description 29
- 239000002502 liposome Substances 0.000 claims description 27
- 238000009472 formulation Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 19
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 19
- 201000002528 pancreatic cancer Diseases 0.000 claims description 19
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 19
- 108700028369 Alleles Proteins 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 claims description 17
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 15
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims description 10
- 238000011260 co-administration Methods 0.000 claims description 7
- 210000005166 vasculature Anatomy 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 206010068873 Adenosquamous cell carcinoma Diseases 0.000 claims description 5
- 208000007569 Giant Cell Tumors Diseases 0.000 claims description 5
- 208000006336 acinar cell carcinoma Diseases 0.000 claims description 5
- 208000009956 adenocarcinoma Diseases 0.000 claims description 5
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims description 5
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 claims description 5
- 208000022669 mucinous neoplasm Diseases 0.000 claims description 5
- 210000000496 pancreas Anatomy 0.000 claims description 5
- 208000002820 pancreatoblastoma Diseases 0.000 claims description 5
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 230000003474 anti-emetic effect Effects 0.000 claims description 4
- 239000002111 antiemetic agent Substances 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- -1 irinotecan sucrose octasulfate salt Chemical class 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 239000000232 Lipid Bilayer Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 210000003499 exocrine gland Anatomy 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 239000002356 single layer Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 229940127089 cytotoxic agent Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261659211P | 2012-06-13 | 2012-06-13 | |
| US61/659,211 | 2012-06-13 | ||
| US201361784382P | 2013-03-14 | 2013-03-14 | |
| US61/784,382 | 2013-03-14 | ||
| PCT/US2013/045495 WO2013188586A1 (en) | 2012-06-13 | 2013-06-12 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017113465A Division JP2017149783A (ja) | 2012-06-13 | 2017-06-08 | リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523355A JP2015523355A (ja) | 2015-08-13 |
| JP2015523355A5 true JP2015523355A5 (enExample) | 2016-02-04 |
| JP6310911B2 JP6310911B2 (ja) | 2018-04-11 |
Family
ID=48692681
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015517405A Active JP6310911B2 (ja) | 2012-06-13 | 2013-06-12 | リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法 |
| JP2017113465A Withdrawn JP2017149783A (ja) | 2012-06-13 | 2017-06-08 | リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法 |
| JP2019087488A Active JP6857210B2 (ja) | 2012-06-13 | 2019-05-07 | リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017113465A Withdrawn JP2017149783A (ja) | 2012-06-13 | 2017-06-08 | リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法 |
| JP2019087488A Active JP6857210B2 (ja) | 2012-06-13 | 2019-05-07 | リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (10) | US9452162B2 (enExample) |
| EP (3) | EP2861210B1 (enExample) |
| JP (3) | JP6310911B2 (enExample) |
| KR (3) | KR101997206B1 (enExample) |
| CN (2) | CN110051631A (enExample) |
| AU (3) | AU2013202947B2 (enExample) |
| BR (1) | BR112014031088A8 (enExample) |
| CA (1) | CA2875824C (enExample) |
| DK (2) | DK2861210T3 (enExample) |
| ES (2) | ES2880089T3 (enExample) |
| IL (3) | IL294886A (enExample) |
| IN (1) | IN2014DN11099A (enExample) |
| MX (1) | MX376937B (enExample) |
| NZ (1) | NZ702469A (enExample) |
| PL (2) | PL3266456T3 (enExample) |
| PT (2) | PT3266456T (enExample) |
| RU (1) | RU2663450C2 (enExample) |
| SI (2) | SI3266456T1 (enExample) |
| TW (3) | TWI729492B (enExample) |
| WO (1) | WO2013188586A1 (enExample) |
| ZA (1) | ZA201408804B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2424792C2 (ru) | 2004-05-03 | 2011-07-27 | Хермес Байесайенсиз, Инк. | Липосомы, используемые для доставки лекарственных средств |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| JP6758195B2 (ja) * | 2014-01-14 | 2020-09-23 | ネクター セラピューティクス | 併用ベースの治療方法 |
| MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
| JP7113619B2 (ja) * | 2014-12-09 | 2022-08-05 | イプセン バイオファーム リミティド | リポソーマルイリノテカンによる乳がんの治療 |
| WO2016168451A1 (en) * | 2015-04-14 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| HK1257216A1 (zh) | 2015-08-20 | 2019-10-18 | 益普生生物制药有限公司 | 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法 |
| BR112018002941B1 (pt) * | 2015-08-21 | 2023-12-05 | Ipsen Biopharm Ltd | Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas |
| US10894044B2 (en) | 2015-09-16 | 2021-01-19 | Board Of Regents, The University Of Texas System | Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer |
| BR112018006922B1 (pt) | 2015-10-16 | 2023-11-21 | Ipsen Biopharm Ltd | Composições de irinotecano lipossômico estabilizado para armazenamento |
| WO2017172678A1 (en) * | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| MA45046A (fr) * | 2016-05-18 | 2019-03-27 | Ipsen Biopharm Ltd | Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| US12291570B2 (en) * | 2018-10-17 | 2025-05-06 | Biolinerx Ltd. | Treatment of metastatic pancreatic adenocarcinoma |
| WO2020148744A1 (en) * | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
| US20220072087A1 (en) * | 2019-01-17 | 2022-03-10 | Biolinerx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
| WO2021142202A1 (en) | 2020-01-10 | 2021-07-15 | R-Pharm Us Operating Llc | Compositions of ixabepilone |
| WO2021142020A1 (en) * | 2020-01-10 | 2021-07-15 | Tyndall Formulation Services, LLC | Formulations of sn-38 with poly(amino acid) block polymers |
| US11286344B2 (en) | 2020-01-10 | 2022-03-29 | Tyndall Formulation Services, LLC | Polymer excipients for drug delivery applications |
| JP2024536275A (ja) * | 2021-10-03 | 2024-10-04 | システィミューン， インク． | がんを治療する方法及びその医薬組成物 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2628659A (en) * | 1951-01-17 | 1953-02-17 | Charles R Carpenter | Convertible furniture article |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5538954A (en) | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
| US5783568A (en) | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| DE19605024A1 (de) | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
| EP0949906A4 (en) | 1996-10-22 | 2004-11-24 | Hermes Biosciences Inc | LIPOSOMES LOADED WITH ACTIVE SUBSTANCE AND THEIR PRODUCTION METHOD |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| CA2346879A1 (en) | 1998-09-16 | 2000-04-27 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
| US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| ATE341310T1 (de) | 2000-02-04 | 2006-10-15 | Lipoxen Technologies Ltd | Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome |
| US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| JP4679028B2 (ja) | 2000-05-15 | 2011-04-27 | セルジーン コーポレイション | 結腸直腸癌を治療するための組成物および方法 |
| AU7038501A (en) | 2000-06-30 | 2002-01-14 | Inex Pharmaceuticals Corp | Liposomal antineoplastic drugs and uses thereof |
| TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
| JP2004525138A (ja) | 2001-03-26 | 2004-08-19 | アルザ・コーポレーシヨン | 治療剤の改良された細胞内送達のためのリポソーム組成物 |
| US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
| WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
| JP2005504759A (ja) | 2001-07-23 | 2005-02-17 | エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト | Ｃｙｐ３ａ５に基づいたがんの改善治療の手段及び方法 |
| CA2399169A1 (en) * | 2001-09-07 | 2003-03-07 | Queen's University At Kingston | Diagnostic methods for determining susceptibility to convulsive conditions |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| ITBO20010610A1 (it) | 2001-10-05 | 2003-04-05 | Haworth S P A | Dispositivo per la connessione di gambe ad elementi di arredamento, ed elemento di arredamento comprendente tale dispositivo |
| AU2003237864B2 (en) | 2002-05-15 | 2008-12-18 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
| WO2003101475A1 (en) | 2002-05-31 | 2003-12-11 | Transmolecular Inc. | Treatment of cell proliferative disorders with chlorotoxin |
| WO2004035032A2 (en) | 2002-08-20 | 2004-04-29 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| RU2424792C2 (ru) | 2004-05-03 | 2011-07-27 | Хермес Байесайенсиз, Инк. | Липосомы, используемые для доставки лекарственных средств |
| AP2255A (en) | 2004-06-01 | 2011-07-21 | Yakult Honsha Kk | Irinotecan preparation. |
| EP1761264A1 (en) * | 2004-06-03 | 2007-03-14 | F.Hoffmann-La Roche Ag | Treatment with irinotecan (cpt-11) and an egfr-inhibitor |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| EP1951239A2 (en) | 2005-10-25 | 2008-08-06 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
| EP1954286A2 (en) * | 2005-11-10 | 2008-08-13 | SmithKline Beecham Corporation | Inhibitors of akt activity |
| WO2007076117A2 (en) * | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
| PL2338487T3 (pl) | 2006-01-17 | 2014-03-31 | Abbvie Bahamas Ltd | Terapia skojarzona z inhibitorami PARP |
| WO2007109184A2 (en) | 2006-03-16 | 2007-09-27 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
| JP5307538B2 (ja) * | 2006-11-30 | 2013-10-02 | アークレイ株式会社 | Ｕｇｔ１ａ１遺伝子増幅用プライマーセット、それを含むｕｇｔ１ａ１遺伝子増幅用試薬およびその用途 |
| HRP20131113T1 (hr) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
| ES2550759T3 (es) | 2007-08-17 | 2015-11-12 | Celator Pharmaceuticals, Inc. | Formulaciones farmacológicas de platino mejoradas |
| EP2197917A1 (en) | 2007-09-28 | 2010-06-23 | Universitätsspital Basel | Immunoliposomes for treatment of cancer |
| NZ586123A (en) | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors |
| CA2708157A1 (en) | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| TWI444384B (zh) * | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| US20110104256A1 (en) | 2008-03-25 | 2011-05-05 | Yaolin Wang | Methods for treating or preventing colorectal cancer |
| US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
| MX2010011145A (es) | 2008-04-11 | 2011-04-11 | Merrimack Pharmaceuticals Inc | Enlazadores de la albumina de suero humana y conjugados de la misma. |
| US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
| JP2012503640A (ja) * | 2008-09-26 | 2012-02-09 | センター リージョナル ド ルッタ コントレ ル キャンサー ダンジェ | Ｆｏｌｆｉｒｉ治療における５−フルオロウラシル用量の個別最適化方法 |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| JP2012525371A (ja) | 2009-05-01 | 2012-10-22 | オンコザイム・ファーマ・インコーポレイテッド | 癌を治療するためのペンタミジンの組み合わせ |
| ES2547698T3 (es) | 2009-12-03 | 2015-10-08 | Jiangsu Hengrui Medicine Co., Ltd. | Liposoma de irinotecán o su clorhidrato y método de preparación del mismo |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| EP2595618A1 (en) | 2010-07-19 | 2013-05-29 | BiPar Sciences, Inc. | Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| CA2806076A1 (en) | 2010-07-22 | 2012-01-26 | The Regents Of The University Of California | Anti-tumor antigen antibodies and methods of use |
| RU2541100C2 (ru) | 2010-09-03 | 2015-02-10 | Боард Оф Регентс Оф Зе Юниверсити Оф Небраска | Способ и композиция для лечения рака |
| JP6208582B2 (ja) | 2010-12-06 | 2017-10-04 | メリマック ファーマシューティカルズ インコーポレーティッド | アントラサイクリン系化学療法剤を含有しているｅｒｂｂ２標的免疫リポソームによる治療における心臓毒性を抑制するための用量及び投与 |
| US9226984B2 (en) | 2010-12-14 | 2016-01-05 | Technical University of Denmark and Rigshospitalet | Entrapment of radionuclides in nanoparticle compositions |
| WO2012112730A2 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
| HRP20170713T1 (hr) | 2011-04-19 | 2017-07-14 | Merrimack Pharmaceuticals, Inc. | Bispecifično anti-igf-1r i anti-erbb3 antitijelo |
| JO3283B1 (ar) * | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| AU2013201584A1 (en) * | 2012-03-12 | 2013-09-26 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody |
| WO2013158803A1 (en) | 2012-04-17 | 2013-10-24 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for non-invasive imaging |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| WO2014113167A1 (en) | 2012-12-14 | 2014-07-24 | Merrimack Pharmaceuticals, Inc. | Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents |
| UA117581C2 (uk) | 2013-03-27 | 2018-08-27 | Тайхо Фармасьютікал Ко., Лтд. | Протипухлинний лікарський засіб, який включає низькодозований гідрохлориду іринотекану гідрат |
| WO2015031536A1 (en) | 2013-08-27 | 2015-03-05 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
| US20160303264A1 (en) | 2013-10-23 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for non-invasive imaging and drug delivery |
| JP7113619B2 (ja) | 2014-12-09 | 2022-08-05 | イプセン バイオファーム リミティド | リポソーマルイリノテカンによる乳がんの治療 |
| WO2016168451A1 (en) | 2015-04-14 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment |
| HK1257216A1 (zh) | 2015-08-20 | 2019-10-18 | 益普生生物制药有限公司 | 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法 |
| BR112018002941B1 (pt) | 2015-08-21 | 2023-12-05 | Ipsen Biopharm Ltd | Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas |
| BR112018006922B1 (pt) | 2015-10-16 | 2023-11-21 | Ipsen Biopharm Ltd | Composições de irinotecano lipossômico estabilizado para armazenamento |
| US20170202840A1 (en) | 2016-01-14 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Treatment of pancreatic cancer with liposomal irinotecan |
| WO2017172678A1 (en) | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| US20170333421A1 (en) | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Population Pharmacokinetics of Liposomal Irinotecan |
| MA45046A (fr) | 2016-05-18 | 2019-03-27 | Ipsen Biopharm Ltd | Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
-
2013
- 2013-04-08 AU AU2013202947A patent/AU2013202947B2/en active Active
- 2013-06-11 TW TW108132921A patent/TWI729492B/zh active
- 2013-06-11 TW TW102120630A patent/TWI630924B/zh active
- 2013-06-11 TW TW107116721A patent/TW201831168A/zh unknown
- 2013-06-12 PT PT171690985T patent/PT3266456T/pt unknown
- 2013-06-12 KR KR1020177024678A patent/KR101997206B1/ko active Active
- 2013-06-12 KR KR1020157000450A patent/KR101776808B1/ko active Active
- 2013-06-12 RU RU2015100529A patent/RU2663450C2/ru active
- 2013-06-12 EP EP13731230.2A patent/EP2861210B1/en not_active Revoked
- 2013-06-12 MX MX2014015391A patent/MX376937B/es active IP Right Grant
- 2013-06-12 ES ES17169098T patent/ES2880089T3/es active Active
- 2013-06-12 KR KR1020197018996A patent/KR20190107010A/ko not_active Withdrawn
- 2013-06-12 PL PL17169098T patent/PL3266456T3/pl unknown
- 2013-06-12 IN IN11099DEN2014 patent/IN2014DN11099A/en unknown
- 2013-06-12 JP JP2015517405A patent/JP6310911B2/ja active Active
- 2013-06-12 PT PT137312302T patent/PT2861210T/pt unknown
- 2013-06-12 IL IL294886A patent/IL294886A/en unknown
- 2013-06-12 BR BR112014031088A patent/BR112014031088A8/pt not_active Application Discontinuation
- 2013-06-12 DK DK13731230.2T patent/DK2861210T3/en active
- 2013-06-12 CN CN201910188153.6A patent/CN110051631A/zh active Pending
- 2013-06-12 EP EP17169098.5A patent/EP3266456B1/en active Active
- 2013-06-12 NZ NZ702469A patent/NZ702469A/en unknown
- 2013-06-12 PL PL13731230T patent/PL2861210T3/pl unknown
- 2013-06-12 DK DK17169098.5T patent/DK3266456T3/da active
- 2013-06-12 US US14/406,776 patent/US9452162B2/en active Active
- 2013-06-12 CA CA2875824A patent/CA2875824C/en active Active
- 2013-06-12 AU AU2013274287A patent/AU2013274287B2/en active Active
- 2013-06-12 EP EP21171689.9A patent/EP3919048A1/en active Pending
- 2013-06-12 IL IL235937A patent/IL235937B/en unknown
- 2013-06-12 ES ES13731230.2T patent/ES2632915T3/es active Active
- 2013-06-12 SI SI201331912T patent/SI3266456T1/sl unknown
- 2013-06-12 SI SI201330697T patent/SI2861210T1/sl unknown
- 2013-06-12 WO PCT/US2013/045495 patent/WO2013188586A1/en not_active Ceased
- 2013-06-12 CN CN201380036765.4A patent/CN104717961A/zh active Pending
-
2014
- 2014-12-02 ZA ZA2014/08804A patent/ZA201408804B/en unknown
-
2015
- 2015-07-29 US US14/812,950 patent/US9339497B2/en active Active
- 2015-09-03 US US14/844,500 patent/US9364473B2/en active Active
- 2015-09-11 US US14/851,111 patent/US9492442B2/en active Active
-
2016
- 2016-03-03 US US15/059,640 patent/US20160228428A1/en not_active Abandoned
- 2016-11-02 US US15/341,377 patent/US20170065578A1/en not_active Abandoned
-
2017
- 2017-06-08 JP JP2017113465A patent/JP2017149783A/ja not_active Withdrawn
- 2017-07-18 US US15/652,513 patent/US20170368056A1/en not_active Abandoned
-
2018
- 2018-03-19 AU AU2018201942A patent/AU2018201942B2/en active Active
- 2018-06-19 US US16/012,351 patent/US10980795B2/en active Active
-
2019
- 2019-05-07 JP JP2019087488A patent/JP6857210B2/ja active Active
-
2021
- 2021-03-17 US US17/204,278 patent/US20220096458A1/en not_active Abandoned
-
2023
- 2023-07-20 IL IL304631A patent/IL304631A/en unknown
-
2024
- 2024-03-22 US US18/613,609 patent/US20240226090A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523355A5 (enExample) | ||
| Ortiz et al. | Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications | |
| Fan et al. | Development of liposomal formulations: From concept to clinical investigations | |
| TWI599369B (zh) | 包含阿柏西普（ａｆｌｉｂｅｒｃｅｐｔ）、醛葉酸、５－氟尿嘧啶（５－ｆｕ）及伊立替康（ｉｒｉｎｏｔｅｃａｎ）（ｆｏｌｆｉｒｉ）之組合物 | |
| DE60027039T2 (de) | Cisplatin- und andere Wirkstoffe oder Gene eingekapselt in Liposomen zur menschlichen Krebstherapie | |
| Camacho et al. | DAFODIL: a novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy | |
| JP2019533684A5 (enExample) | ||
| JP2014088444A5 (enExample) | ||
| JP2018528185A5 (enExample) | ||
| RU2015100529A (ru) | Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомный иринотекан | |
| BR112018002941B1 (pt) | Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas | |
| JP2013526545A5 (enExample) | ||
| Ando et al. | Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed | |
| Bhosale et al. | Current perspectives on novel drug carrier systems and therapies for management of pancreatic cancer: An updated inclusive review | |
| Nicolaides et al. | Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group | |
| JP2008540364A5 (enExample) | ||
| Mohammad-Jafari et al. | Cisplatin-based liposomal nanocarriers for drug delivery in lung cancer therapy: Recent progress and future outlooks | |
| Krasnopolskii et al. | Technologies and perspectives of liposomal drug application in clinical practice | |
| TWI760319B (zh) | 乳癌治療 | |
| He et al. | Co-delivery liposomes of irinotecan hydrochloride and curcumin in the synergistic treatment of colorectal cancer | |
| WO2013022827A1 (en) | Method of treating acute myelogenous leukemia | |
| Gao et al. | Preclinical development and phase I study of ZSYY001, a polymeric micellar paclitaxel for advanced solid tumor | |
| Yang et al. | Nanoplatform-mediated autophagy regulation and combined anti-tumor therapy for resistant tumors | |
| Leighl et al. | Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer | |
| JP2014502992A (ja) | 癌のための併用療法 |